Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Teva Pharmaceutical Industries (NYSE:TEVA) and raises the price target from $17 to $20.
May 09, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Teva Pharmaceutical Industries and raises the price target from $17 to $20.
The upgrade in price target by a reputable analyst like Balaji Prasad from Barclays indicates a strong confidence in Teva Pharmaceutical Industries' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in TEVA's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100